IVN201--therapy with a construct containing functional fusion peptides.

Area of Science:

• Immunology
• Allergy Research
• Drug Development

Background:

• Conventional allergen immunotherapy faces challenges with efficacy, safety, and patient compliance.
• Intralymphatic immunotherapy (ILIT) offers a targeted approach by administering allergens directly into lymph nodes.
• Modular-Antigen-Transportation (MAT) proteins are designed for enhanced antigen presentation and immune response modulation.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel immunotherapy, IVN201, for cat dander allergy.
• To assess the potential of combining ILIT with MAT technology for improved allergen tolerance.
• To compare the safety and efficacy profile of IVN201 with existing cat allergen treatments.

Main Methods:

• Development of IVN201, a fusion peptide combining Fel d 1 allergen with MAT technology for ILIT.
• Administration of IVN201 via intralymphatic injection in a murine anaphylaxis model.
• In vitro stimulation assays using basophil leukocytes from allergic patients.

Main Results:

• IVN201 demonstrated allergen tolerance induction in a preclinical model.
• Intralymphatic immunotherapy (ILIT) with MAT proteins showed potential for reduced treatment duration and improved patient compliance in prior studies.
• Stimulation assays suggested a potentially improved safety profile for IVN201 compared to cat extract or recombinant Fel d 1.

Conclusions:

• The combination of ILIT and MAT technology, as exemplified by IVN201, presents a promising strategy for cat dander allergy immunotherapy.
• This novel approach may offer enhanced safety, efficacy, and patient compliance compared to conventional methods.
• Further clinical investigation is warranted to confirm the therapeutic potential of IVN201 in allergic individuals.